The next chapter of the right-wing war on the Affordable Care Act involves a case that targets the preventative care that ...

But just seven years ago, and despite living with HIV for nearly half his life, Duffy was remarkably healthy, working in ...

Discover the latest advancements in HIV prevention and how they offer hope for reducing infections, especially in the Black ...

After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a ...

Here are some of the findings from UNAIDS' new report on HIV and human rights, and what they could mean for the fight against ...

Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

Hopkins said that lenacapavir was expected to be reviewed by the U.S. Food and Drug Administration in 2025, with the potential to dramatically reduce HIV infection. "This will be a critical next step ...

Among treatment-naive people with HIV, dolutegravir/lamivudine showed viral suppression comparable with those of other ...

Although the association between HIV and long COVID was inconclusive, the prevalence of long COVID in patients with HIV was ...

The government provides HIV medicines free of charge. Yet in one Indigenous territory, cases and deaths are increasing at an ...

Every week, 4000 young women contract HIV. Discover hidden barriers to prevention and innovative solutions that can change ...

Gilead Sciences reached a settlement with the Justice Department and HHS that resolves a five-year legal dispute regarding patents for its HIV prevention drugs, Truvada and Descovy.